Literature DB >> 3226359

The adenosine hypothesis of epilepsy.

D R O'Brien1.   

Abstract

The present communication summarizes a variety of diverse observations indicating that adenine ribo-nucleoside (ARN), or adenosine, may play an important role as an endogenous anti-epileptic compound in the central nervous system. From such observations has evolved an hypothesis which states that defects in the synthesis, release, action and/or degradation of ARN may be a causative factor in some forms of epilepsy. Of particular interest is the emerging realization that the adenosine system may be a common factor in the mechanism of action of many otherwise unrelated anticonvulsant compounds. Thus, a more detailed understanding of the ARN system and its role in the control of cerebral activity may lead to rational strategies for the development of efficacious therapeutic agents having greater specificity and fewer side effects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3226359     DOI: 10.1016/0306-9877(88)90007-2

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  3 in total

1.  Evidence for evoked release of adenosine and glutamate from cultured cerebellar granule cells.

Authors:  A Schousboe; A Frandsen; J Drejer
Journal:  Neurochem Res       Date:  1989-09       Impact factor: 3.996

2.  Role of adenosine in the antiepileptic effects of deep brain stimulation.

Authors:  Maisa F Miranda; Clement Hamani; Antônio-Carlos G de Almeida; Beatriz O Amorim; Carlos E Macedo; Maria José S Fernandes; José N Nobrega; Mayra C Aarão; Ana Paula Madureira; Antônio M Rodrigues; Monica L Andersen; Sergio Tufik; Luiz E Mello; Luciene Covolan
Journal:  Front Cell Neurosci       Date:  2014-10-02       Impact factor: 5.505

3.  Adenosine-A2A Receptor Signaling Plays a Crucial Role in Sudden Unexpected Death in Epilepsy.

Authors:  Hai-Ying Shen; Sadie B Baer; Raey Gesese; John M Cook; Landen Weltha; Shayla Q Coffman; Jie Wu; Jiang-Fan Chen; Ming Gao; Teng Ji
Journal:  Front Pharmacol       Date:  2022-06-09       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.